Literature DB >> 29187371

Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a "U-shaped" relationship.

Mingjun Shi1, Brianna Flores1, Peng Li1,2, Nancy Gillings1, Kathryn L McMillan1, Jianfeng Ye1, Lily Jun-Shen Huang3, Sachdev S Sidhu4, Yong-Ping Zhong5, Maria T Grompe5, Philip R Streeter5, Orson W Moe1,6,7, Ming Chang Hu1,6.   

Abstract

The erythropoietin receptor (EpoR) is widely expressed but its renoprotective action is unexplored. To examine the role of EpoR in vivo in the kidney, we induced acute kidney injury (AKI) by ischemia-reperfusion in mice with different EpoR bioactivities in the kidney. EpoR bioactivity was reduced by knockin of wild-type human EpoR, which is hypofunctional relative to murine EpoR, and a renal tubule-specific EpoR knockout. These mice had lower EPO/EpoR activity and lower autophagy flux in renal tubules. Upon AKI induction, they exhibited worse renal function and structural damage, more apoptosis at the acute stage (<7 days), and slower recovery with more tubulointerstitial fibrosis at the subacute stage (14 days). In contrast, mice with hyperactive EpoR signaling from knockin of a constitutively active human EpoR had higher autophagic flux, milder kidney damage, and better renal function at the acute stage but, surprisingly, worse tubulointerstitial fibrosis and renal function at the subacute stage. Either excess or deficient EpoR activity in the kidney was associated with abnormal peritubular capillaries and tubular hypoxia, creating a "U-shaped" relationship. The direct effects of EpoR on tubular cells were confirmed in vitro by a hydrogen peroxide model using primary cultured proximal tubule cells with different EpoR activities. In summary, normal erythropoietin (EPO)/EpoR signaling in renal tubules provides defense against renal tubular injury maintains the autophagy-apoptosis balance and peritubular capillary integrity. High and low EPO/EpoR bioactivities both lead to vascular defect, and high EpoR activity overides the tubular protective effects in AKI recovery.

Entities:  

Keywords:  AKI; EpoR; autophagy; peritubular capillary; tubulointerstitial fibrosis

Mesh:

Substances:

Year:  2017        PMID: 29187371      PMCID: PMC5966758          DOI: 10.1152/ajprenal.00306.2017

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  96 in total

1.  Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury.

Authors:  Glenda C Gobe; Nigel C Bennett; Malcolm West; Paul Colditz; Lindsay Brown; David A Vesey; David W Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-08

2.  Erythropoietin promotes bone formation through EphrinB2/EphB4 signaling.

Authors:  C Li; C Shi; J Kim; Y Chen; S Ni; L Jiang; C Zheng; D Li; J Hou; R S Taichman; H Sun
Journal:  J Dent Res       Date:  2015-01-13       Impact factor: 6.116

3.  Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney.

Authors:  Henrik Dimke; Matthew A Sparks; Benjamin R Thomson; Sebastian Frische; Thomas M Coffman; Susan E Quaggin
Journal:  J Am Soc Nephrol       Date:  2014-11-10       Impact factor: 10.121

4.  Erythropoietin stimulates bone formation, cell proliferation, and angiogenesis in a femoral segmental defect model in mice.

Authors:  J H Holstein; M Orth; C Scheuer; A Tami; S C Becker; P Garcia; T Histing; P Mörsdorf; M Klein; T Pohlemann; M D Menger
Journal:  Bone       Date:  2011-08-09       Impact factor: 4.398

Review 5.  Cardiovascular effects of erythropoietin an update.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Zvonimir S Katusic
Journal:  Adv Pharmacol       Date:  2010

6.  JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy.

Authors:  Yongjie Wei; Sophie Pattingre; Sangita Sinha; Michael Bassik; Beth Levine
Journal:  Mol Cell       Date:  2008-06-20       Impact factor: 17.970

7.  The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury.

Authors:  Anja Haase-Fielitz; Rinaldo Bellomo; Prasad Devarajan; Michael Bennett; David Story; George Matalanis; Ulrich Frei; Duska Dragun; Michael Haase
Journal:  Nephrol Dial Transplant       Date:  2009-05-27       Impact factor: 5.992

8.  Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety.

Authors:  Ji-Ho Kim; Jae-Kwang Shim; Jong-Wook Song; Young Song; Hye-Bin Kim; Young-Lan Kwak
Journal:  Crit Care       Date:  2013-10-24       Impact factor: 9.097

9.  Estrogen administered after cardiac arrest and cardiopulmonary resuscitation ameliorates acute kidney injury in a sex- and age-specific manner.

Authors:  Mizuko Ikeda; Thomas Swide; Alexandra Vayl; Tim Lahm; Sharon Anderson; Michael P Hutchens
Journal:  Crit Care       Date:  2015-09-18       Impact factor: 9.097

10.  The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection.

Authors:  Ming-Chang Hu; Mingjun Shi; Han J Cho; Jianning Zhang; Alevtina Pavlenco; Shuzhen Liu; Sachdev Sidhu; Lily J-S Huang; Orson W Moe
Journal:  Kidney Int       Date:  2013-05-01       Impact factor: 10.612

View more
  15 in total

1.  Beclin 1/Bcl-2 complex-dependent autophagy activity modulates renal susceptibility to ischemia-reperfusion injury and mediates renoprotection by Klotho.

Authors:  Peng Li; Mingjun Shi; Jenny Maique; Joy Shaffer; Shirley Yan; Orson W Moe; Ming Chang Hu
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-27

2.  In vivo evidence for therapeutic applications of beclin 1 to promote recovery and inhibit fibrosis after acute kidney injury.

Authors:  Mingjun Shi; Jenny Maique; Sierra Shepard; Peng Li; Olivia Seli; Orson W Moe; Ming Chang Hu
Journal:  Kidney Int       Date:  2021-11-01       Impact factor: 10.612

3.  The tripartite interaction of phosphate, autophagy, and αKlotho in health maintenance.

Authors:  Mingjun Shi; Jenny Maique; Joy Shaffer; Taylor Davidson; Salwa Sebti; Álvaro F Fernández; Zhongju Zou; Shirley Yan; Beth Levine; Orson W Moe; Ming Chang Hu
Journal:  FASEB J       Date:  2020-01-05       Impact factor: 5.191

Review 4.  New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR.

Authors:  Kenneth Maiese
Journal:  Front Biosci (Landmark Ed)       Date:  2020-06-01

5.  The combination of vitamin D3 and erythropoietin alleviates acute kidney injury induced by ischemia-reperfusion via inhibiting inflammation and apoptosis.

Authors:  Long-Yan Qin; Xin Lin; Juan Liu; Rong Dong; Jing Yuan; Yan Zha
Journal:  Iran J Basic Med Sci       Date:  2021-02       Impact factor: 2.699

6.  High Phosphate Induces and Klotho Attenuates Kidney Epithelial Senescence and Fibrosis.

Authors:  Jenny Maique; Brianna Flores; Mingjun Shi; Sierra Shepard; Zhiyong Zhou; Shirely Yan; Orson W Moe; Ming Chang Hu
Journal:  Front Pharmacol       Date:  2020-08-20       Impact factor: 5.810

7.  PPAR γ/TLR4/TGF-β1 axis mediates the protection effect of erythropoietin on cyclosporin A-induced chronic nephropathy in rat.

Authors:  Bin Liu; Ping Tan
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

Review 8.  Peritubular Capillary Rarefaction: An Underappreciated Regulator of CKD Progression.

Authors:  Yujiro Kida
Journal:  Int J Mol Sci       Date:  2020-11-04       Impact factor: 5.923

9.  Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor.

Authors:  Megumi Oshima; Akinori Hara; Tadashi Toyama; Min Jun; Carol Pollock; Meg Jardine; Stephen Harrap; Neil Poulter; Mark E Cooper; Mark Woodward; John Chalmers; Vlado Perkovic; Muh Geot Wong; Takashi Wada
Journal:  Kidney Int Rep       Date:  2020-11-10

Review 10.  Erythropoietin Receptor/β Common Receptor: A Shining Light on Acute Kidney Injury Induced by Ischemia-Reperfusion.

Authors:  Yuanyuan Wu; Bin Yang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.